Serine protease specific monoclonal antibodies and their use
AssigneeFuso Pharmaceutical Industries, Ltd.
InventorsKatsuya Kominami, Akira Okui, Shinichi Mitsui, Nozomi Yamaguchi
Life of this patent
Estimating the term…
Abstract
A monoclonal antibody binding selectively to neurosin obtained from hybridomas, in particular, strain 2B2-6 and strain S2E5 showing stable proliferation ability. These hydridomas are obtained by fusing mouse spleen cells having a high antibody titer against neurosin with mouse-derived myeloma cells, screening fused cells being highly reactive with neurosin, and thus producing an antibody binding specifically to neurosin. By using this antibody, various diseases in which neurosin participates can be diagnosed.
Claims13
A hybridoma which is hybridoma cell line 2B2-6 deposited as Accession No. FERM BP-7341.
A hybridoma which is hybridoma cell line S2E5 deposited as Accession No. FERM BP-7342.
Dependencies are inferred from the claim text.